Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT06814496
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Melanoma
- Medullary Thyroid Cancer
- Sinonasal Undifferentiated Carcinoma
- Esthesioneuroblastoma
- Bladder Cancer
- Testicular Cancer
- Glioblastoma Multiforme
- Cervical Cancer
- Large Cell Neuroendocrine Carcinoma of the Lung
- Non Small Cell Lung Cancer
- Merkel Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Arizona
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Banner MD Anderson Cancer Center · Gilbert, AZ
- Arizona Cancer Center at UMC North/University Medical Center · Tucson, AZ
Washington · 1
- University of Washington Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.